Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet

References

• Bachau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 2007;28:393-7
   PubMed Web of Science ®Google Scholar
• Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008;19:110-24
   PubMed Web of Science ®Google Scholar
• White P, Smith H, Baker N, et al. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 1998;28:266-70
   PubMed Web of Science ®Google Scholar
• Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010;125:S306-13
   PubMed Web of Science ®Google Scholar
• Frew AJ, Powell RJ, Corrigan CJ, et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25
   PubMed Web of Science ®Google Scholar
• Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9
   PubMed Web of Science ®Google Scholar
• Bousquet J, Casale T, Lockey RF, et al. Sub-lingual immunotherapy. World Allergy Organisation position paper 2009. WAO Journal 2009;233-81. Available at: http://www.worldallergy.org/publications/slit-wao-pp_final.pdf
   Google Scholar
• Di Bona D, Plaia A, Scafidi V, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010;126:558-66
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics (SPC). Grazax 75,000 SQ-T oral lyophilisate. Available at: http://www.grazax.com/SiteCollectionDocuments/Grazax.com/About%20Grazax/Grazax_S mPC_MRP_VAR13_15OCT2010.pdf [Last accessed 28 March 2012]
   Google Scholar
• Lombardi C, Incorvaia C, Braga M, et al. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 2009;64:849-54
   PubMed Web of Science ®Google Scholar
• Hejl C, Wurtzen PA, Kleine-Tebbe J, et al. Phleum pratense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009;39:752-9
   PubMed Web of Science ®Google Scholar
• Johansen N, Weber RW, Ipsen H, et al. Extensive cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects. Int Arch Allergy Immunol 2009;150:325-34
   PubMed Web of Science ®Google Scholar
• Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71
   PubMed Web of Science ®Google Scholar
• Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73
   PubMed Web of Science ®Google Scholar
• Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjuntivitis. Allergy 2006;61:185-90
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
   PubMed Web of Science ®Google Scholar
• Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83
   PubMed Web of Science ®Google Scholar
• Juniper EF, Howland WC, Roberts NB, et al. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998;101:163-70
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. EMEA/CHMP/EWP/18504/2006. European Medicines Agency, 2008. Available at: www.ema.europa.eu [Last accessed 22 Nov 2011]
   Google Scholar
• Durham S, Emminger W, Riis B, et al. Efficacy and safety of SQ-standardised grass allergy immunotherapy tablet in European and North American adults. Allergy 2011;66(Suppl 94):105-63
   Google Scholar
• Bufe A, Tholstrup B, Maloney J, et al. Efficacy and safety of SQ-standardised grass allergy immunotherapy tablet in European and North American children and adolescents. Allergy 2011;66(Suppl. 94):164-319
   Google Scholar
• Dehlink E, Eiwegger T, Gerstmayr M, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006;36:32-9
   PubMed Web of Science ®Google Scholar
• Rolinck-Werninghaus C, Kopp M, Liebke C, et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005;136:134-41
   PubMed Web of Science ®Google Scholar
• Malling HJ, Lund L, Ipsen H, et al. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006;16:162-8
   PubMed Web of Science ®Google Scholar
• Aberer W, Hawranek T, Reider N, et al. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol 2007;17:131-6
   PubMed Web of Science ®Google Scholar
• Panizo C, Cimarra M, Gonzalez-Mancebo E, et al. In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets. J Investig Allergol Clin Immunol 2010;20:454-62
   PubMed Web of Science ®Google Scholar
• Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007;62:954-7
   PubMed Web of Science ®Google Scholar
• Durham SR, Birk AO, Andersen JS. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy 2011;66:120-3
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64(Suppl 91):1-59
   PubMed Web of Science ®Google Scholar
• Juniper EF, Ståhl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005;115(3 Suppl 1):S390-413
   PubMedGoogle Scholar
• Davies RR, Smith LP. Forecasting the start and severity of the hay fever season. Clin Allergy 1973;3:263-7
   PubMedGoogle Scholar
• Emberlin J, Jaeger S, Dominguez-Vilches E, et al. Temporal and geographical variations in grass pollen seasons in areas of western Europe: an analysis of season dates at sites of European pollen information system. Aerobiologia 2000;16:373-9
   Web of Science ®Google Scholar
• D’Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007;62:976-90
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-8
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25
   PubMed Web of Science ®Google Scholar
• Lombardi C, Gargioni S, Venturi S, et al. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. J Investig Allergol Clin Immunol 2001;11:41-5
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75
   PubMed Web of Science ®Google Scholar
• Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:1394-401
   PubMed Web of Science ®Google Scholar
• Valovirta E, Herland Berstad A, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjuctivitis. Clin Ther 2011;33:1537-1546
   Google Scholar
• Nassar S, Vestenb婠U, Beriot-Mathiot A, et al. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008;63:1624-1629
   Google Scholar